JP2017532959A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532959A5
JP2017532959A5 JP2017519013A JP2017519013A JP2017532959A5 JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5 JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017519013 A JP2017519013 A JP 2017519013A JP 2017532959 A5 JP2017532959 A5 JP 2017532959A5
Authority
JP
Japan
Prior art keywords
subject
gene
threshold
mdm2i
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017519013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532959A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/079389 external-priority patent/WO2016056673A1/en
Publication of JP2017532959A publication Critical patent/JP2017532959A/ja
Publication of JP2017532959A5 publication Critical patent/JP2017532959A5/ja
Withdrawn legal-status Critical Current

Links

JP2017519013A 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム Withdrawn JP2017532959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061992P 2014-10-09 2014-10-09
US62/061,992 2014-10-09
PCT/JP2015/079389 WO2016056673A1 (en) 2014-10-09 2015-10-09 Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017532959A JP2017532959A (ja) 2017-11-09
JP2017532959A5 true JP2017532959A5 (enExample) 2018-11-22

Family

ID=54396934

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519013A Withdrawn JP2017532959A (ja) 2014-10-09 2015-10-09 Mdm2阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム

Country Status (4)

Country Link
US (1) US20170283885A1 (enExample)
EP (1) EP3204514A1 (enExample)
JP (1) JP2017532959A (enExample)
WO (1) WO2016056673A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその使用
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN109843329A (zh) * 2016-10-17 2019-06-04 第一三共株式会社 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法
CN107974502B (zh) * 2016-10-19 2021-07-02 北京大学人民医院 一种用于同时检测nbpf10、tsfm、prb2及diaph1基因突变的试剂盒
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
RU2747746C2 (ru) * 2018-10-24 2021-05-13 Общество с ограниченной ответственностью «Онкобокс» Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
WO2021228814A1 (en) * 2020-05-15 2021-11-18 ETH Zürich Mdm2 inhibitor response prediction method
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023009174A1 (en) * 2021-07-30 2023-02-02 Oregon Health & Science University Methods for predicting lymph node status, likelihood of metastasis, and/or overall prognosis in patients with melanoma
CN118398086A (zh) * 2024-04-19 2024-07-26 山东云海国创云计算装备产业创新中心有限公司 抗癌药物反应预测方法、装置、计算机设备及存储介质

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380892B1 (en) * 2009-01-16 2014-04-02 Daiichi Sankyo Company, Limited Imidazothiazole derivative having proline ring structure
SI2684880T1 (en) * 2011-03-10 2018-08-31 Daiichi Sankyo Company, Limited DERIVAT DISPIROPYROLIDINE
US20120328692A1 (en) * 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
HUE045880T2 (hu) * 2012-07-31 2020-01-28 Novartis Ag A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek
WO2014065760A1 (en) * 2012-10-25 2014-05-01 Agency For Science, Technology And Research Methods for determining resistance against molecules targeting proteins
CA2912547A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Similar Documents

Publication Publication Date Title
JP2017532959A5 (enExample)
Westphal et al. Circulating biomarkers for gliomas
Fry et al. Activation of inflammation/NF-κB signaling in infants born to arsenic-exposed mothers
JP2017508442A5 (enExample)
JP2021501318A5 (enExample)
Slaby et al. Significant overexpression of Hsp110 gene during colorectal cancer progression
Anaka et al. Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors
Yuan et al. Identification of a Nine Immune‐Related lncRNA Signature as a Novel Diagnostic Biomarker for Hepatocellular Carcinoma
Liu et al. A single-cell transcriptional landscape of immune cells shows disease-specific changes of T cell and macrophage populations in human achalasia
Zhang et al. Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma
JP2022522354A (ja) 肝がん再発予測用dnaメチル化マーカー及びその用途
Yu et al. Genome-wide analysis of genetic variations assisted by Ingenuity Pathway Analysis to comprehensively investigate potential genetic targets associated with the progression of hepatocellular carcinoma
CN109402254B (zh) 一种预测胰腺癌术后生存的LncRNA模型及检测试剂盒
Cruz‐Granados et al. Multiomic‐based immune response profiling in migraine, vestibular migraine and Meniere's disease
JP2018538247A5 (enExample)
Li et al. Significance of pyroptosis-related gene in the diagnosis and classification of rheumatoid arthritis
Gonzalez Curto et al. The PAX-FOXO1s trigger fast trans-differentiation of chick embryonic neural cells into alveolar rhabdomyosarcoma with tissue invasive properties limited by S phase entry inhibition
Niu et al. Integrative Disulfidptosis‐Based Risk Assessment for Prognostic Stratification and Immune Profiling in Glioma
Wang et al. Identification of several senescence‐associated genes signature in head and neck squamous cell carcinoma
Lu et al. Dysregulation of TFDP1 and of the cell cycle pathway in high-grade glioblastoma multiforme: a bioinformatic analysis
Yang et al. Single‐cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers
CN113736879A (zh) 用于小细胞肺癌患者预后的系统及其应用
WO2021249355A1 (zh) 用于选择化疗响应患者组的生物标志物和方法及其用途
Wei et al. Identification and validation of IFI44 as a novel biomarker for primary Sjögren’s syndrome
JP2014501496A5 (enExample)